Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330–44. https://doi.org/10.1016/j.ejca.2014.01.029.

Article  PubMed  Google Scholar 

Cancer Statistics in Japan. Cancer Information Services, Cancer type statistical information Gastric cancer. National Cancer Center, Japan. https://ganjoho.jp/public/cancer/stomach/patients.html [in Japanese]. Accessed Jun 2, 2025.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer, version 2. (2022).

Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.

Article  CAS  PubMed  Google Scholar 

Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47. https://doi.org/10.1016/S1470-2045(21)00692-6.

Article  CAS  PubMed  Google Scholar 

Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. https://doi.org/10.1126/science.aan3706.

Article  CAS  PubMed  Google Scholar 

Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9. https://doi.org/10.1126/science.aac4255.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84. https://doi.org/10.1126/science.aad1329.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–44. https://doi.org/10.1093/annonc/mdy103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and Poplar trials. Ann Oncol. 2020;31:525–31. https://doi.org/10.1016/j.annonc.2020.01.006.

Article  CAS  PubMed  Google Scholar 

Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C. Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol. 2021;12:716317. https://doi.org/10.3389/fimmu.2021.716317.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8. https://doi.org/10.1136/gutjnl-2015-310376.

Article  CAS  PubMed  Google Scholar 

Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56. https://doi.org/10.1136/gutjnl-2015-310861.

Article  CAS  PubMed  Google Scholar 

Shibano M, Takahashi M, Nakatsukasa H, Ishigami Y, Toyokawa T, Taira K, Kawaguchi T, Nakamura Y, Kaneda H. Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer. Immunotherapy. 2025;17:331–8. https://doi.org/10.1080/1750743X.2025.2491300.

Article  CAS  PubMed  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7. https://doi.org/10.1016/S0140-6736(07)61602-X.

Article  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed Jun 16, 2025.

Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255–60. https://doi.org/10.1002/sim.4780050306.

Article  CAS  PubMed  Google Scholar 

Koo SH, Deng J, Ang DSW, et al. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J. 2019;60:512–21. https://doi.org/10.11622/smedj.2018152.

Article  PubMed  PubMed Central  Google Scholar 

Sands SA, Tsau S, Yankee TM, Parker BL, Ericsson AC, LeVine SM. The effect of omeprazole on the development of experimental autoimmune encephalomyelitis in C57BL/6J and SJL/J mice. BMC Res Notes. 2014;7:605. https://doi.org/10.1186/1756-0500-7-605.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. https://doi.org/10.1126/science.aan4236.

Article  CAS  PubMed  Google Scholar 

Wada A, Enokida T, Okano S, Sato M, Tanaka H, Ueda Y, Fujisawa T, Takeshita N, Tanaka N, Tahara M. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2023;184:30–8. https://doi.org/10.1016/j.ejca.2023.02.011.

Article  CAS  PubMed  Google Scholar 

Takahashi M, Nakatsukasa H, Shibano M, Ishigami Y, Oka T, Tani Y, Kawaguchi T, Nakamura Y, Kaneda H. Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors. Int J Clin Oncol. 2025;30:1582–92. https://doi.org/10.1007/s10147-025-02805-2.

Article  CAS  PubMed  Google Scholar